Sign In
Buy MYNZ
$0.700
+0 (+0%)
At Close: Jun 03, 2026
Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY
07:30am, Friday, 13'th Mar 2026
BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
07:30am, Wednesday, 11'th Mar 2026
BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed NV (NASDAQ:MYNZ) Short Interest Update
04:40am, Sunday, 01'st Feb 2026
Mainz Biomed NV (NASDAQ: MYNZ - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 255,35
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
09:15am, Wednesday, 14'th Jan 2026
BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
2 Small-Cap Biotechs That Could Reward Patient Investors
09:52am, Friday, 12'th Dec 2025
Speculative investors and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement.
Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next?
02:15am, Saturday, 22'nd Nov 2025
Mainz Biomed NV (NASDAQ: MYNZ - Get Free Report)'s stock price fell 5.8% during mid-day trading on Friday. The company traded as low as $0.92 and last traded at $0.9990. 283,999 shares traded hands du
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
08:01am, Tuesday, 18'th Nov 2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
08:01am, Wednesday, 12'th Nov 2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
08:01am, Monday, 10'th Nov 2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
09:00am, Wednesday, 08'th Oct 2025
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results fro
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
08:01am, Tuesday, 02'nd Sep 2025
BERKELEY, Calif. and MAINZ, Germany, Sept.
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
08:01am, Wednesday, 13'th Aug 2025
BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
10:22am, Monday, 04'th Aug 2025
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
08:01am, Wednesday, 23'rd Jul 2025
BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
MYNZ Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
